Comprehensive Analysis of Proteinuria and Nephrotic Syndrome Using the Japanese Adverse Drug Event Reporting Database.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14002

Sho Masago, Kenta Yamaoka, Mayako Uchida, Yoshihiro Uesawa, Kennosuke Yorifuji, Tadashi Shimizu

{"title":"Comprehensive Analysis of Proteinuria and Nephrotic Syndrome Using the Japanese Adverse Drug Event Reporting Database.","authors":"Sho Masago, Kenta Yamaoka, Mayako Uchida, Yoshihiro Uesawa, Kennosuke Yorifuji, Tadashi Shimizu","doi":"10.21873/invivo.14002","DOIUrl":null,"url":null,"abstract":"Background/aim: This study aimed to identify potential drug associations between proteinuria and nephrotic syndrome (NS) using the Japanese Adverse Drug Event Report (JADER) database.Patients and methods: We extracted data reported in JADER between April 2004 and May 2023, and conducted a comprehensive disproportionality analysis of spontaneous adverse event reports to identify drugs potentially linked to proteinuria and NS.Results: Our analysis identified 20 and 32 drugs associated with proteinuria and NS, respectively. Notably, anti-vascular endothelial growth factor (anti-VEGF) agents represented 45% (9/20) of proteinuria-associated drugs and 34% (11/32) of NS-associated drugs. Furthermore, the association between anti-VEGF agents and these adverse events appeared to be independent of the route of administration, sex, or clinical background.Conclusion: These findings suggest that anti-VEGF agents play a significant role in the development of proteinuria and NS. Given the widespread use of anti-VEGF therapy, heightened vigilance, routine monitoring, and timely interventions are crucial to mitigate these risks and improve patient outcomes.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2073-2084"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223660/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: This study aimed to identify potential drug associations between proteinuria and nephrotic syndrome (NS) using the Japanese Adverse Drug Event Report (JADER) database.

Patients and methods: We extracted data reported in JADER between April 2004 and May 2023, and conducted a comprehensive disproportionality analysis of spontaneous adverse event reports to identify drugs potentially linked to proteinuria and NS.

Results: Our analysis identified 20 and 32 drugs associated with proteinuria and NS, respectively. Notably, anti-vascular endothelial growth factor (anti-VEGF) agents represented 45% (9/20) of proteinuria-associated drugs and 34% (11/32) of NS-associated drugs. Furthermore, the association between anti-VEGF agents and these adverse events appeared to be independent of the route of administration, sex, or clinical background.

Conclusion: These findings suggest that anti-VEGF agents play a significant role in the development of proteinuria and NS. Given the widespread use of anti-VEGF therapy, heightened vigilance, routine monitoring, and timely interventions are crucial to mitigate these risks and improve patient outcomes.

查看原文本刊更多论文

利用日本不良药物事件报告数据库对蛋白尿和肾病综合征进行综合分析。

背景/目的：本研究旨在利用日本不良药物事件报告（JADER）数据库确定蛋白尿和肾病综合征（NS）之间的潜在药物关联。患者和方法：我们提取了2004年4月至2023年5月在JADER上报道的数据，并对自发性不良事件报告进行了全面的不成比例分析，以确定可能与蛋白尿和NS相关的药物。结果：我们的分析分别确定了20种和32种与蛋白尿和NS相关的药物。值得注意的是，抗血管内皮生长因子（anti-VEGF）类药物占蛋白尿相关药物的45%(9/20)，占ns相关药物的34%（11/32）。此外，抗vegf药物与这些不良事件之间的关联似乎与给药途径、性别或临床背景无关。结论：上述结果提示抗vegf药物在蛋白尿和NS的发生中起重要作用。鉴于抗vegf治疗的广泛应用，提高警惕、常规监测和及时干预对于减轻这些风险和改善患者预后至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.